Elevance Health gave back ground this week, falling 6.3% to $397.80 — erasing the gains that had briefly carried the stock above its consensus mean target and putting options traders on edge just four weeks before the next earnings print.
The clearest signal this week is in options. Defensive positioning has jumped to its most elevated reading of the past month, with the put/call ratio hitting 0.83 — more than two standard deviations above its 20-day average of 0.70. That's the highest defensive skew of the past year, narrowly trailing the 52-week peak of 0.91. The shift happened fast: as recently as June 9 the PCR was 0.67, squarely in neutral territory. The move in the past week tells you that investors bought protection into the pullback, not ahead of it.
Short interest adds a secondary layer of caution. Bears rebuilt positions through June, with short interest rising 8% on the week and 33% over the past month to around 3% of the free float — the highest level in the 30-day window. The borrow market, however, provides no squeeze signal. Availability is extraordinarily loose, with roughly 134 million shares available to borrow versus fewer than 7 million currently shorted. Cost to borrow has also fallen sharply, down 33% on the week to just 0.37%. The setup reads as bears adding exposure at a comfortable cost, not a crowded trade under pressure.
The Street remains broadly bullish, but the stock has now drifted back below targets set just weeks ago. The analyst upgrade wave documented here last week — eleven target raises, zero cuts, with JP Morgan at $476, Barclays at $480, and Deutsche Bank at $498 — leaves a consensus mean near $416 against a current price of $397.80. That's roughly 4.5% implied upside to consensus, with the more aggressive targets pointing to 20–25%. The bull case rests on Medicare Advantage margin expansion of over 150 basis points in 2026 and improving Medicaid dynamics; the bear case centers on earnings per share estimates that have already been cut to around $25.54, continued medical cost pressure, and Medicaid membership declines. Morgan Stanley's Equal-Weight target of $404 — raised from $352 on June 4 — sits closest to where the stock actually trades, making it the most instructive data point in the current range. The PE multiple of 14.2x and EV/EBITDA of 10.8x both compressed modestly through the week, consistent with the price pullback rather than any fundamental re-rating.
Among peers, ELV's weekly decline of 6.3% was sharper than most. UNH dropped 1.3% and MOH fell 1.4%, while CNC bore the brunt with a 7.3% loss — suggesting sector-level pressure rather than ELV-specific deterioration. CVS bucked the trend, up 3.8% on the week, pointing to diverging investor views on the government-program mix across the group. Invesco's addition of roughly 687,000 shares in the most recent reporting period stands out against the otherwise incremental institutional moves; combined with the recent $870,000 director purchase in early March at $289, institutional accumulation at lower prices has been a feature of ELV's recovery trade.
Q2 results are scheduled for July 15. Given that the last print produced a 5.5% one-day gain and a 14.8% five-day move, the combination of elevated put/call ratio, rebuilding short interest, and a stock now sitting below most analyst targets means the earnings setup will be scrutinised closely — less for whether the Medicare Advantage margin story is intact, and more for whether Medicaid guidance can stabilise expectations and bring the bears back offside.
See the live data behind this article on ORTEX.
Open ELV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
